Nab-paclitaxel for breast cancer: A new formulation with an improved safety profile and greater efficacy

ArticleinExpert Review of Anti-infective Therapy 7(7):919-43 · August 2007with11 Reads
DOI: 10.1586/14737140.7.7.919 · Source: PubMed
Taxanes, paclitaxel and docetaxel, are among the most effective agents used to treat breast cancer. Nab-paclitaxel (ABI-007, Abraxane) is paclitaxel encapsulated in albumin. This differs from the more conventional formulation which uses cremophor to increase the solubility of paclitaxel (CrEL-paclitaxel). In a randomized trial that formed the basis of its regulatory approval in the USA, 3-weekly nab-paclitaxel induced a higher response rate and longer time to progression than CrEL-paclitaxel in patients with metastatic breast cancer. Except for grade 3 sensory neuropathy, nab-paclitaxel was also safer. An interim analysis from a more recent randomized Phase II trial suggests that weekly nab-paclitaxel is more effective and safer than either 3-weekly nab-paclitaxel or 3-weekly docetaxel. The superior efficacy of nab-paclitaxel is presumably due to the improved safety profile, which allows for the administration of higher doses, a greater proportion of which actually reaches the tumor. Observations on the development of nab-paclitaxel have important implications for our understanding of dose response in the use of cytotoxic drugs to treat all forms of cancer. Although it is not yet clear whether nab-paclitaxel can be routinely substituted for CrEL-paclitaxel or docetaxel in breast cancer treatment regimens, it seems highly likely that this will occur within the next 5 years.
    • "Nab-paclitaxel (nab-PTX) is paclitaxel albumin-stabilized nanoparticle formulation. It can be administered without ethanol or steroid premedication and delivered to tumor tissue efficiently [1]. Currently nab-PTX has been approved for breast, gastric, lung and pancreatic cancer in Japan. "
    Article · Jan 2016 · Expert opinion on biological therapy
    • "Albumin is a natural carrier of endogenous hydrophobic molecules bound in a reversible non-covalent manner and enhances penetration by albumin receptor-mediated (gp60) endothelial transcytosis [324]. Albumin binds to therapeutic peptide or protein covalently or physically resulting enhances the stability and half-life of the drug325326327328329330331332. Stable and negatively charged Nab-paclitaxel nanoparticles with size of approximately 0.1– 0.2 mm was prepared by encapsulating paclitaxel in albumin nanoparticle which can pass through the leaky capillary junctions in the tumor bed more easily [333]. "
    [Show abstract] [Hide abstract] ABSTRACT: Brain tumor is one of the most challenging diseases to treat. The major obstacle in the specific drug delivery to brain is blood-brain barrier (BBB). Mostly available anti-cancer drugs are large hydrophobic molecules which have limited permeability via BBB. Therefore, it is clear that the protective barriers confining the passage of the foreign particles into the brain are the main impediment for the brain drug delivery. Hence, the major challenge in drug development and delivery for the neurological diseases is to design non-invasive nanocarrier systems that can assist controlled and targeted drug delivery to the specific regions of the brain. In this review article, our major focus to treat brain tumor by study numerous strategies includes intracerebral implants, BBB disruption, intraventricular infusion, convection-enhanced delivery, intra-arterial drug delivery, intrathecal drug delivery, injection, catheters, pumps, microdialysis, RNA interference, antisense therapy, gene therapy, monoclonal/cationic antibodies conjugate, endogenous transporters, lipophilic analogues, prodrugs, efflux transporters, direct conjugation of antitumor drugs, direct targeting of liposomes, nanoparticles, solid-lipid nanoparticles, polymeric micelles, dendrimers and albumin-based drug carriers.
    Full-text · Article · Apr 2015
    • "Although this novel HIF-1a RNA antagonist showed evidence of tumor shrinkage post-modulation of HIF-1a mRNA levels, a number of patients reported some adverse effects [61]. Earlier nanoparticle-based approaches were reported to encapsulate drugs and deliver them specifically to the tumor site preventing nonspecific toxicity [62]. This approach has been successfully extended to deliver siRNA to hypoxic tumor sites, which has shown improved antitumor efficacy [63]. "
    [Show abstract] [Hide abstract] ABSTRACT: Introduction: Cancer cells acclimatize to the harsh tumor microenvironment by altering cellular metabolism in favor of aerobic glycolysis. This process provides a source of energy and also generates essential components for macromolecular biosynthesis, which enables cellular survival. As the dependence of cancer cells on glycolysis affects tumorigenesis, it has become an attractive target for therapeutic intervention. Several preclinical studies have shown the effectiveness of using biological targets from the glycolytic pathway for anticancer therapy. Areas covered: This review provides an insight into the glycolytic pathway, highlighting potential targets for glycolytic inhibition. We then discuss recent advancement in delivery strategies that have the potential to circumvent some of the problems posed by current glycolytic inhibitors, enabling resurrection of abandoned therapeutic agents. Expert opinion: Targeting the glycolysis pathway is a tactical approach for cancer therapy. However, the current nonspecific therapeutic strategies have several drawbacks such as poor bioavailability, unfavorable pharmacokinetic profile and associated nonspecific toxicity, thereby limiting preclinical investigation. In recent years, nanoparticle systems have received recognition for the delivery of therapeutic agents directly to the tumor tissue. Thus, it is envisaged that this strategy can be expanded for the delivery of current glycolytic inhibitors specifically to tumor tissues providing improved anticancer activity.
    Full-text · Article · Apr 2014
Show more

  • undefined · undefined
  • undefined · undefined
  • undefined · undefined